Generalized Dystonia, Segmental Dystonia, Tardive Dystonia
Conditions
Brief summary
The main objective of the trial is to study the technical feasibility of the implantation of a new electrode Monocontact deep brain stimulation electrode in dystonia.
Detailed description
Deep brain stimulation (DBS) is a validated therapy for treating dystonia and other movement disorders. The main therapeutical target used for treating dystonic syndromes is the internal globus pallidum (GPi). Given the morphology and the topography of this nucleus and, based on the experience of an efficient therapy by using only one or two contacts out of the available four contacts of the standard DBS lead, we designed two new electrodes, one one contact-electrode and one two contact-electrodes, with the aim to limit side effects related to internal globus pallidum DBS and to provide a more homogeneous electric field around the electrode within the GPi and maintaining the same therapeutical outcome. The main objective of the trial is to study the technical feasibility of the implantation of a new one contact-electrode (Monopolar DBS Lead Model 09064-40cm) for treating isolated generalized/segmental dystonia or tardive dystonia. The second main objective of the study is to assess the safety of the implantation of the new device. The secondary objective is to explore the therapeutical effect of DBS using the new monocontact electrode and to study the electrical field generated around the monocontact electrode within the GPi. The study is prospective and patients are recruited from a Tertiary Movement Disorders Clinic. Seven subjects will be recruited for the study.
Interventions
DEVICEElectrode deep brain stimulation (Monopolar DBS Lead Model 09064-40cm)
Deep brain stimulation surgery with implantation of one contact-electrode deep brain stimulation electrodes bilaterally in the internal globus pallidum for treating dystonia
Sponsors
University Hospital, Montpellier
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 64 Years
Healthy volunteers
No
Inclusion criteria
* Age superior to 18 years and inferior to 65 years * Generalized or segmental isolated dystonia or tardive dystonia * Diagnosis is based on history, clinical examination, check-up without abnormalities and normal brain MRI allowing exclusion of secondary and degenerative dystonias * Unsufficient response to pharmacological treatment (improvement \< 30/% on clinical dystonia scales) * No comorbidity interfering with general anesthesia, or representing contraindication for neurosurgical procedure or with the follow-up during the trial * Consent of the patient * Insurance affiliation * Follow-up possible for 12 months * Available insurance for the operated patient
Exclusion criteria
* No possibility for clinical follow-up * Acquired dystonia except for tardive dystonia * MRI or generalized anesthesia contraindicated * Anticoagulant treatment or antiaggregant treatment * Pregnancy * Ongoing participation to another clinical trial * Guardianship or Trusteeship * Person deprived of liberty
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Technical feasibility of new electrode implantation | One year | The feasibility of the implantation is evaluated by stereotaxic frame placement, site of incision, burr hole size and location, technique for insertion, connection with the extension cables to the neurostimulator, measure of the impedances, duration of the surgery, MRI control for lead position, comparison of the artefacts of the leads with the artefacts of the standard electrodes. |
| Safety of new electrode implantation (evaluated by the occurence of side effects) | One year | The safety of the implantation is evaluated by the occurence of side effects after the implatation and along the follow-up. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| clinical effect of deep brain stimulation using one contact-electrodes (Burke Fahn Marsden's dystonia rating scale and the Toronto Western Spasmodic Torticollis Rating Scale) | One year | Clinical change as measured by the decrease of the motor and disability of the patient (Burke Fahn Marsden's dystonia rating scale and the Toronto Western Spasmodic Torticollis Rating Scale). |
Countries
France
Outcome results
None listed